Earnings results for Allogene Therapeutics (NASDAQ:ALLO)
Allogene Therapeutics, Inc. is expected* to report earnings on 02/25/2021 after market close. The report will be for the fiscal Quarter ending Dec 2020. According to Zacks Investment Research, based on 10 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.56. The reported EPS for the same quarter last year was $-0.58.
Analyst Opinion on Allogene Therapeutics (NASDAQ:ALLO)
17 Wall Street analysts have issued ratings and price targets for Allogene Therapeutics in the last 12 months. Their average twelve-month price target is $49.92, predicting that the stock has a possible upside of 45.68%. The high price target for ALLO is $70.00 and the low price target for ALLO is $27.00. There are currently 4 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Allogene Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.76, and is based on 13 buy ratings, 4 hold ratings, and no sell ratings. According to analysts’ consensus price target of $49.92, Allogene Therapeutics has a forecasted upside of 45.7% from its current price of $34.27. Allogene Therapeutics has only been the subject of 3 research reports in the past 90 days.
Dividend Strength: Allogene Therapeutics (NASDAQ:ALLO)
Allogene Therapeutics does not currently pay a dividend. Allogene Therapeutics does not have a long track record of dividend growth.
Insiders buying/selling: Allogene Therapeutics (NASDAQ:ALLO)
In the past three months, Allogene Therapeutics insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $461,550.00 in company stock. Only 31.30% of the stock of Allogene Therapeutics is held by insiders. 59.86% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Allogene Therapeutics (NASDAQ:ALLO
Earnings for Allogene Therapeutics are expected to decrease in the coming year, from ($2.13) to ($2.39) per share. The P/E ratio of Allogene Therapeutics is -16.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Allogene Therapeutics is -16.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Allogene Therapeutics has a P/B Ratio of 6.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here